Applied Medical Biotechnology - Bewerkingsoverzicht

R0895938: /* 15 January 2026 */

2026-01-16T12:51:21Z

15 January 2026

← Oudere versie		Versie van 16 jan 2026 14:51
Regel 14:		Regel 14:
	#* 3 patients with DNMT3A mutants: VAF=0.02, VAF = 0.01, VAF = 0.05		#* 3 patients with DNMT3A mutants: VAF=0.02, VAF = 0.01, VAF = 0.05
	#* 1 patient with a TET2 mutant: VAF = 0.01		#* 1 patient with a TET2 mutant: VAF = 0.01
	#* 1 patient with ~~mutation is~~ DNMT3A (VAF = 0.49), TET2 (VAF = 0.38) and P53 (VAF = 0.26)		#* 1 patient with mutations in DNMT3A (VAF = 0.49), TET2 (VAF = 0.38) and P53 (VAF = 0.26)
	# 4 Concepts to explain		# 4 Concepts to explain
	#* PROTAC		#* PROTAC

R0895938: /* 15 January 2026 */

2026-01-16T08:29:36Z

15 January 2026

← Oudere versie		Versie van 16 jan 2026 10:29
Regel 17:		Regel 17:
	# 4 Concepts to explain		# 4 Concepts to explain
	#* PROTAC		#* PROTAC
	#* ~~CART~~		#* CAR-T cell therapy
	#* Irreversible vs reversible kinase inhibitor		#* Irreversible vs reversible kinase inhibitor
	#* How can you know lung cancer is caused by smoking?		#* How can you know lung cancer is caused by smoking?

R0895938: /* 15 January 2026 */

2026-01-16T08:26:26Z

15 January 2026

← Oudere versie		Versie van 16 jan 2026 10:26
Regel 19:		Regel 19:
	#* CART		#* CART
	#* Irreversible vs reversible kinase inhibitor		#* Irreversible vs reversible kinase inhibitor
	#* ~~Another I don't remember~~		#* How can you know lung cancer is caused by smoking?

	Van der steen:		Van der steen:

R0895938: /* 15 January 2026 */

2026-01-16T08:25:39Z

15 January 2026

← Oudere versie		Versie van 16 jan 2026 10:25
Regel 27:		Regel 27:
	Lambrechts:		Lambrechts:
	# Give 2 examples of an inducible gene expression system. Describe them schematically.		# Give 2 examples of an inducible gene expression system. Describe them schematically.
	# Somatic copy number alterations are frequent in solid tumors. We discussed 2 examples of how these copy number alterations can be used as biomarkers:		# Somatic copy number alterations are frequent in solid tumors. We discussed 2 examples of how these copy number alterations can be used as biomarkers: 1/ to tailor PARP inhibitors to ovarian cancer patients or 2/ to aid in the pre-symptomatic detection of cancer in pregnant women. Give the name of both genetic tests and briefly describe how they work (give their underlying principle).
	1/ to tailor PARP inhibitors to ovarian cancer patients or 2/ to aid in the pre-symptomatic detection of cancer in pregnant women. Give the name of both genetic tests and briefly describe how they work (give their underlying principle).

	===09 January 2026===		===09 January 2026===

R0895938: /* 15 January 2026 */

2026-01-16T08:24:28Z

15 January 2026

← Oudere versie		Versie van 16 jan 2026 10:24
Regel 11:		Regel 11:

	Cools:		Cools:
	# In a whole genome study on 100 patients they found the following mutations:		# In a whole genome study on 100 patients they found the following mutations: What can you conclude from this? Wat advise would you give these patients? What risks do these patients have?
	#* 3 patients with DNMT3A mutants: VAF=0.02, VAF = 0.01, VAF = 0.05		#* 3 patients with DNMT3A mutants: VAF=0.02, VAF = 0.01, VAF = 0.05
	#* 1 patient with a TET2 mutant: VAF = 0.01		#* 1 patient with a TET2 mutant: VAF = 0.01
	#* 1 patient with mutation is DNMT3A (VAF = 0.49), TET2 (VAF = 0.38) and P53 (VAF = 0.26)		#* 1 patient with mutation is DNMT3A (VAF = 0.49), TET2 (VAF = 0.38) and P53 (VAF = 0.26)
	~~What can you conclude from this? Wat advise would you give these patients? What risks do these patients have?~~
	# 4 Concepts to explain		# 4 Concepts to explain
	#* PROTAC		#* PROTAC

R0895938: /* Exam questions */

2026-01-16T08:23:52Z

Exam questions

← Oudere versie		Versie van 16 jan 2026 10:23
Regel 6:		Regel 6:

	==Exam questions==		==Exam questions==

			===15 January 2026===
			Oral parts were with Cools or Van der Steen

			Cools:
			# In a whole genome study on 100 patients they found the following mutations:
			#* 3 patients with DNMT3A mutants: VAF=0.02, VAF = 0.01, VAF = 0.05
			#* 1 patient with a TET2 mutant: VAF = 0.01
			#* 1 patient with mutation is DNMT3A (VAF = 0.49), TET2 (VAF = 0.38) and P53 (VAF = 0.26)
			What can you conclude from this? Wat advise would you give these patients? What risks do these patients have?
			# 4 Concepts to explain
			#* PROTAC
			#* CART
			#* Irreversible vs reversible kinase inhibitor
			#* Another I don't remember

			Van der steen:
			# Type one interferons. How are they used to treat disease? We saw two examples. Explain them both. On what mechanism do they work? In case of INF-beta, does it work better glycosylated or non-glycosylated and why?
			# A group of researchers want to make a small biological against sequestration of malaria. Why could such a drug be useful? We saw to types of drug screens. Describe the differences and (dis)advantages. When developping the anti-sequestration drug, would you go for an intracellular or extracellular target?

			Lambrechts:
			# Give 2 examples of an inducible gene expression system. Describe them schematically.
			# Somatic copy number alterations are frequent in solid tumors. We discussed 2 examples of how these copy number alterations can be used as biomarkers:
			1/ to tailor PARP inhibitors to ovarian cancer patients or 2/ to aid in the pre-symptomatic detection of cancer in pregnant women. Give the name of both genetic tests and briefly describe how they work (give their underlying principle).

	===09 January 2026===		===09 January 2026===

R0890365: /* Exam questions */

2026-01-10T21:02:34Z

Exam questions

← Oudere versie		Versie van 10 jan 2026 23:02
Regel 35:		Regel 35:
	#* mutation signature		#* mutation signature
	#* CAR T-cell		#* CAR T-cell
	#* ?		#* How can we change a transcriptional repressor into an activator

	Lambrechts:		Lambrechts:

R0890365: /* Exam questions */

2026-01-10T21:00:57Z

Exam questions

@@ Regel 25: / Regel 25: @@
 # difluoromethylornithine is a repurposed drug: mechanism(s), discovery process, other thing(s) used for
 # A researcher wants to make a passive immunization therapy for placental malaria. What are the advantages/disadvantages of passive immunization and how does it work? What antigen should be targeted and explain in detail what it does/how it works. Should the antibody be sialylated? How can the antibodies be optimized? Would this therapy be effective? Why (not)?
 ===17 Januari 2025 AM===

R0856695: /* 09 January 2026 */

2026-01-10T11:42:19Z

09 January 2026

← Oudere versie		Versie van 10 jan 2026 13:42
Regel 20:		Regel 20:
	Lambrechts:		Lambrechts:
	# Describe the principle of linkage disequilibrium between SNPs, and indicate in which studies this disequilibrium is being used. How do these studies work? We also discussed how SNPs are being used to predict risk of developing a disease, risk of developing side-effects in response to treatment or to identify the underlying mechanisms of disease. Can you briefly explain?		# Describe the principle of linkage disequilibrium between SNPs, and indicate in which studies this disequilibrium is being used. How do these studies work? We also discussed how SNPs are being used to predict risk of developing a disease, risk of developing side-effects in response to treatment or to identify the underlying mechanisms of disease. Can you briefly explain?
	# Describe ~~schematiccaly~~ how i) chemical and ii) transposon insertional mutagenesis screens work in zebrafish and explain. How would you use a CRISPR screen in the zebrafish (discuss the example highlighted) and would this result in comparable data as in i) and ii). Finally, describe which system you use to induce gene expression in the zebrafish.		# Describe schematicaly how i) chemical and ii) transposon insertional mutagenesis screens work in zebrafish and explain. How would you use a CRISPR screen in the zebrafish (discuss the example highlighted) and would this result in comparable data as in i) and ii). Finally, describe which system you use to induce gene expression in the zebrafish.

	Van den Steen:		Van den Steen:

R0856695: /* 09 January 2026 */

2026-01-10T11:42:10Z

09 January 2026

← Oudere versie		Versie van 10 jan 2026 13:42
Regel 15:		Regel 15:
	#* Bispecific antibodies		#* Bispecific antibodies
	#* Effect deamination on mutations		#* Effect deamination on mutations
	#* Why ~~is there more~~ clonal hematopoiesis ~~seen in older people~~		#* Why does clonal hematopoiesis increase with aging
	#* How can we change a transcriptional repressor into an activator		#* How can we change a transcriptional repressor into an activator